Showing 4261-4270 of 9470 results for "".
- Study: PLLA-SCA Induces Adipogenesis and Volumization of the Hip Dellhttps://practicaldermatology.com/news/study-plla-sca-induces-adipogenesis-and-volumization-hip-dell/2468575/Injecting poly-l-lactic acid (PLLA-SCA) is a safe and effective method for durable volumization and aesthetic improvement of the hip dell, and may promote adipogenesis and elastogenesis, according to a new study published in Dermatologic Surgery. “People have used Sculptra for years, but w
- Study Links Severe AD With Need for Surgery in Glaucoma Patientshttps://practicaldermatology.com/news/study-links-severe-ad-need-surgery-glaucoma-patients/2468562/Patients suffering from both severe atopic dermatitis (AD) and glaucoma are increasingly likely to need surgical intervention for the glaucoma depending on the severity of their AD, according to a new Journal of Glaucoma study. “Association of Atopic Dermatitis and Risk of Glaucoma Surgery
- T-VASI and F-VASI Shown Reliable in Nonsegmental Vitiligo Assessmenthttps://practicaldermatology.com/news/t-vasi-and-f-vasi-shown-reliable-nonsegmental-vitiligo-assessment/2468550/New research confirmed that the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) are reliable and valid tools for measuring meaningful improvement in patients with nonsegmental vitiligo. The study, published in JAMA Dermatology, included 164 adult participa
- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- FDA Approves Emrosi for Rosaceahttps://practicaldermatology.com/news/fda-approves-emrosi-rosacea-treatment/2468543/The US Food and Drug Administration (FDA) has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) as a treatment for inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, Journey Medical (in partnership with Dr.
- CeraVe Expands into Haircare with Launch of Anti-Dandruff and Gentle Hydrating Productshttps://practicaldermatology.com/news/cerave-expands-haircare-launch-anti-dandruff-and-gentle-hydrating-products/2468510/CeraVe has announced the launch of Anti-Dandruff and Gentle Hydrating Products, leadin
- Vichy Dercos Launches Advanced Scalp Line in US Markethttps://practicaldermatology.com/news/vichy-dercos-launches-advanced-scalp-solutions-us-market/2468512/Vichy Decros has announced the US launch of its new three-step system targeting scalp concerns, representing w
- New Acne Solution Prioritizes Skin Barrier Healthhttps://practicaldermatology.com/news/new-acne-solution-prioritizes-skin-barrier-health/2468513/Bioelements announced the launch of the Acne and Pore Activists Collection, a breakthrough four-piece line designed to revolutionize care for oily and acne-prone skin by prioritizing skin barrier health. “Years in the making, this innovative collection was meticulously crafted through exte
- AD Drugs Market Predicted to Grow From $10.5 Billion to $24.5 Billionhttps://practicaldermatology.com/news/ad-drugs-market-predicted-grow-105-billion-245-billion/2468511/A new market research report predicts that the global atopic dermatitis (AD) drugs market will grow at a compound annual growth rate of 9.1% from now through 2033, going from $10.5 billion in 2023 to $24.5 billion by 2033. The report, from market.us, is titled, “Atopic Dermatitis Drugs Mar
- 'Me & My Inner Circle' Launches on World Psoriasis Dayhttps://practicaldermatology.com/news/me-my-inner-circle-launches-world-psoriasis-day/2468497/October 29 is World Psoriasis Day, and Almirall recognized the occasion by launching an awareness campaign called “Me & My Inner Circle,” with the support of the International Federation of Psoriasis Associations (IFPA), the company announced. The campaign features Alma, representing a